Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 1630-1636, 2008. First published August 14, 2008; 10.1373/clinchem.2007.100917
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.100917v1
54/10/1630    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aakre, K. M.
Right arrow Articles by Sandberg, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aakre, K. M.
Right arrow Articles by Sandberg, S.
(Clinical Chemistry. 2008;54:1630-1636.)
© 2008 American Association for Clinical Chemistry, Inc.


Evidence-Based Laboratory Medicine and Test Utilization

Postanalytical External Quality Assessment of Urine Albumin in Primary Health Care: An International Survey

Kristin M. Aakre1,a, Geir Thue2, Sumathi Subramaniam-Haavik2, Tone Bukve2, Howard Morris3, Mathias Müller4, Marijana V. Lovrencic5, Inger Plum6, Kaja Kallion7, Alar Aab8, Marge Kutt9, Philippe Gillery10, Nathalie Schneider10, Andrea R. Horvath11, Rita Onody11, Wytze Oosterhuis12, Carmen Ricos13, Carmen Perich14, Gunnar Nordin15 and Sverre Sandberg1,2

1 Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway;2 The Norwegian Quality Improvement of Primary Care Laboratories (NOKLUS), Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway;3 Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia;4 Institute of Laboratory Diagnostics, Kaiser Franz Joseph Hospital, Vienna, Austria;5 Laboratory of Medical Biochemistry, Vuk Vrhovac University Clinic, Zagreb, Croatia;6 Danish Institute for External Quality Assurance for Laboratories in Health Care (DEKS), Herlev University Hospital, Herlev, Denmark;7 Department of Children’s Hospital, United Laboratories, Clinicum of the University of Tartu, Tartu, Estonia;8 Department of Clinical Chemistry, United Laboratories, Clinicum of the University of Tartu, Tartu, Estonia;9 East Tallinn Central Hospital, Tallinn, Estonia;10 Laboratoire de Biologie et de Recherche Pédiatriques, American Memorial Hospital, CHU de Reims, Reims, France;11 Laboratory Department of Clinical Chemistry, University of Szeged, Szeged, Hungary;12 Department of Clinical Chemistry, St. Elisabeth Hospital, Tilburg, the Netherlands;13 Laboratori Clínic Bon Pastor Barcelona, Barcelona, Spain;14 Analytical Quality Commission of the Spanish Society of Clinical Biochemistry and Molecular Pathology (SEQC), Barcelona, Spain;15 External quality assurance in laboratory medicine in Sweden (Equalis), Uppsala, Sweden.

aAddress correspondence to this author at: Laboratory of Clinical Biochemistry, Haukeland University Hospital, Helse Bergen HF, Postbox 1, 5021 Bergen, Norway. Fax +47 55975976; e-mail kristin.moberg.aakre{at}helse-bergen.no.

background: Microalbuminuria (MA) is recognized as an important risk factor for cardiovascular and renal complications in diabetes. We sought to evaluate how screening for MA is conducted and how urine albumin (UA) results are interpreted in primary care internationally.

methods: General practitioners (GPs) received a case history–based questionnaire depicting a male type 2 diabetes patient in whom UA testing had not been performed. Questions were related to type of urine sample used for UA testing, need for a repeat test, whether UA testing was performed in the office laboratory, and what changes in UA results were considered clinically important [critical difference (CD)]. Participants received national benchmarking feedback reports.

results: We included 2078 GPs from 9 European countries. Spot urine samples were used most commonly for first time office-based testing, whereas timed collections were used to a larger extent for hospital-based repeat tests. Repeat tests were requested by 45%–77% of GPs if the first test was positive. Four different measurement units were used by 70% of participants in estimating clinically important changes in albumin values. Stated CDs varied considerably among GPs, with similar variations in each country. A median CD of 33% was considered clinically important for both improvement and deterioration in MA, corresponding to an achievable analytical imprecision of 14%, when UA is reported as an albumin/creatinine ratio.

conclusions: Guidelines on diagnosing MA are followed only partially, and should be made more practicable, addressing issues such as type of samples, measurement units, and repeat tests.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
W. G. Miller, D. E. Bruns, G. L. Hortin, S. Sandberg, K. M. Aakre, M. J. McQueen, Y. Itoh, J. C. Lieske, D. W. Seccombe, G. Jones, et al.
Current Issues in Measurement and Reporting of Urinary Albumin Excretion
Clin. Chem., January 1, 2009; 55(1): 24 - 38.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. J. McQueen and A. C. Don-Wauchope
Requesting and Interpreting Urine Albumin Measurements in the Primary Health Care Setting
Clin. Chem., October 1, 2008; 54(10): 1595 - 1597.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.